Ipamorelin vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research.
Ipamorelin and Sermorelin are two of the most popular growth hormone stimulating peptides, but they work through different mechanisms. Ipamorelin is a GHRP (Growth Hormone Releasing Peptide) that mimics ghrelin, while Sermorelin is a GHRH (Growth Hormone Releasing Hormone) analog. Understanding their differences is crucial for optimizing GH enhancement protocols.
Quick Comparison
Key Similarities
- Both stimulate natural GH production from the pituitary
- Both produce pulsatile GH release patterns
- Both have good safety profiles with minimal side effects
- Both require subcutaneous injection
- Both work best on an empty stomach
- Both are commonly used for anti-aging and body composition
Key Differences
- Different receptor targets (ghrelin receptor vs GHRH receptor)
- Sermorelin has FDA approval history; Ipamorelin does not
- Ipamorelin typically dosed multiple times daily; Sermorelin once at night
- Ipamorelin may have slight hunger effect; Sermorelin none
- Sermorelin has longer research history; Ipamorelin is newer
- They work synergistically together rather than being alternatives
When to Choose Each
Choose Ipamorelin
Choose Ipamorelin when you want a clean GH secretagogue with minimal side effects, especially as part of a combined GHRP+GHRH protocol. Its selectivity for GH without affecting other hormones makes it the 'cleanest' GHRP option.
Choose Sermorelin
Choose Sermorelin when you prefer a single daily dose before bed and value its FDA approval history and extensive research. It's particularly popular for anti-aging clinics due to its established safety profile.
Can You Stack Them?
Ipamorelin and Sermorelin are often used together in a GHRP+GHRH stack. This combination can produce synergistic GH release that exceeds either peptide alone. The typical protocol is taking both together before bed, with some adding a morning dose. CJC-1295 without DAC (Mod GRF 1-29) is another popular GHRH to combine with Ipamorelin.
Frequently Asked Questions
References
- Raun K, et al. "Ipamorelin selectivity." Eur J Endocrinol, 1998. PMID: 9758455
- Walker RF. "Sermorelin clinical use." Drugs, 2006. PMID: 16929329
Get the Complete Comparison Guide
Download our detailed comparison charts and decision framework.